Literature DB >> 1384628

The role of iron in experimental porphyria and porphyria cutanea tarda.

P D Siersema1, R P van Helvoirt, M I Cleton-Soeteman, W C de Bruijn, J H Wilson, H G van Eijk.   

Abstract

Porphyria cutanea tarda (PCT) and experimental porphyria are characterized by a decreased activity of the enzyme uroporphyrinogen decarboxylase, and accumulation of uroporphyrins and heptacarboxylporphyrins in the liver. Iron (Fe) plays an important role in PCT and experimental porphyria. Biochemically and electron microscopically, we examined the relationship between Fe and porphyrins in liver tissue of C57BL/10 mice made porphyric by administration of iron dextran as Imferon (IMF), and in liver biopsies of patients with symptomatic PCT. Accumulation of uroporphyrins and heptacarboxylporphyrins, and an increased amount of Fe were observed in livers of mice treated with IMF and in liver biopsies of patients with PCT. In mice treated with IMF, the activity of uroporphyrinogen decarboxylase was decreased. Both in livers of mice treated with IMF and in livers of patients with PCT, needle-like structures, representing uroporphyrin crystals, were observed by electron microscopy. Uroporphyrin crystals and Fe (as ferritin) were observed in the same hepatocyte. Moreover, there was a striking morphological correlation between uroporphyrin crystals and ferritin-Fe, suggesting a role for (ferritin-)Fe in the pathogenesis of porphyria.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384628     DOI: 10.1007/BF02786238

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  29 in total

1.  Quantitative energy-filtered image analysis in cytochemistry. II. Morphometric analysis of element-distribution images.

Authors:  C W Sorber; J B Van Dort; P C Ringeling; M I Cleton-Soeteman; W C De Bruijn
Journal:  Ultramicroscopy       Date:  1990-01       Impact factor: 2.689

2.  Determination of iron to phosphorus ratios of iron storage compounds in patients with iron overload: a chemical and electron probe X-ray microanalysis.

Authors:  M I Cleton; E J Frenkel; W C de Bruijn; J J Marx
Journal:  Hepatology       Date:  1986 Sep-Oct       Impact factor: 17.425

3.  Evidence for cytochrome P450-mediated oxidation of uroporphyrinogen by cell-free liver extracts from chick embryos treated with 3-methylcholanthrene.

Authors:  P Sinclair; R Lambrecht; J Sinclair
Journal:  Biochem Biophys Res Commun       Date:  1987-08-14       Impact factor: 3.575

4.  Heterozygosity for HLA-linked hemochromatosis as a likely cause of the hepatic siderosis associated with sporadic porphyria cutanea tarda.

Authors:  J P Kushner; C Q Edwards; M M Dadone; M H Skolnick
Journal:  Gastroenterology       Date:  1985-05       Impact factor: 22.682

5.  The pathology of the liver in porphyria cutanea tarda.

Authors:  J M Cortés; H Oliva; F J Paradinas; C Hernandez-Guío
Journal:  Histopathology       Date:  1980-09       Impact factor: 5.087

6.  Iron exchange between ferritin and transferrin in vitro.

Authors:  D C Harris
Journal:  Biochemistry       Date:  1978-07-25       Impact factor: 3.162

7.  Synergism of iron and hexachlorobenzene inhibits hepatic uroporphyrinogen decarboxylase in inbred mice.

Authors:  A G Smith; J E Francis
Journal:  Biochem J       Date:  1983-09-15       Impact factor: 3.857

8.  Familial porphyria cutanea tarda: the pattern of porphyrins formed from porphobilinogen by hemolysates.

Authors:  M A Alleman; J H Wilson; J W van den Berg; A Edixhoven-Bosdijk; L M van Gastel-Quist
Journal:  Clin Chem       Date:  1982-05       Impact factor: 8.327

9.  The involvement of iron and lipid peroxidation in the pathogenesis of HCB induced porphyria.

Authors:  M A Alleman; J F Koster; J H Wilson; A Edixhoven-Bosdijk; R G Slee; M J Kroos; H G von Eijk
Journal:  Biochem Pharmacol       Date:  1985-01-15       Impact factor: 5.858

10.  Role of iron in the hydrogen peroxide-dependent oxidation of hexahydroporphyrins (porphyrinogens): a possible mechanism for the exacerbation by iron of hepatic uroporphyria.

Authors:  F De Matteis
Journal:  Mol Pharmacol       Date:  1988-04       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.